YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Compass Therapeutics, Inc.(NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, point…
Compass Therapeutics The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig. Compass does not believe that a new trial is warranted prior to submitting a BLA based on the…
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this yea…
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today an…
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company's main story is tovecimig, an experimental cancer treatment being developed for biliary tract cancer, which affects th…
Compass Therapeutics BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple huma…
Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D expenses rose to $13.4 million, while…
Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Value & Momentum Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company's share was trading at $987.0…
Compass Therapeutics BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple huma…
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. Th…
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy. On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 from $13 and maintained a Buy rating. T…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Baird upgraded Old Dominion(ODFL) to Neutr…
The major averages were broadly lower amid stalled peace negotiations between the U.S. and Iran as well as new escalation in the Strait of Hormuz. Investors are also balancing continued strength in corporate earnings and AI-driven optimism…
Compass Therapeutics says a treatment evaluating its cancer treatment didn’t meet the secondary endpoint for an unexpected reason. Continue Reading
(RTTNews) - Compass Therapeutics, Inc. (CMPX), a clinical-stage biopharmaceutical company, will review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing the Tovecimig combination with Paclitaxel in patie…
Compass Therapeutics Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing p…
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock surged 237.08% in the past year and 16.05% year-to-date. On April 7, John Newman of Cannaccord Genuity maintained a…
The S&P 500 futures in Friday's pre-market trading were up on hopes of a peace deal with Iran to end the Middle East war. Yesterday, President Trump said a deal was expected “fairly soon.” While that’s good news for global economies, the r…
On February 17, 2026, ENAVATE Sciences GP, LLC disclosed a buy of 157,800 shares of Zenas BioPharma(NASDAQ:ZBIO), an estimated $5.19 million trade based on quarterly average pricing. ENAVATE Sciences added 157,800 shares of Zenas BioPharma…
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the anal…
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap…
Palo Alto Investors LP initiated a new position in Compass Therapeutics(NASDAQ:CMPX), buying 2,532,419 shares during the quarter for a position value of $13,599,090 as of December 31, 2025, according to a February 17, 2026, SEC filing. Wha…
Key Points Purchased 2,532,419 shares in CMPX; position value was $13,599,090 as of December 31, 2025 Quarter-end value of the CMPX stake was $13,599,090, resulting from the new position initiated during the quarter Transaction represented…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ResMed (RMD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorabl…
We came across a bullish thesis on Compass Therapeutics, Inc. on r/stocks by Cute_Confidence6033. In this article, we will summarize the bulls’ thesis on CMPX. Compass Therapeutics, Inc.'s share was trading at $5.70 as of January 16th.Tays…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recent performance snapshot for Compass Therapeutics (CMPX) Compass Therapeutics (CMPX) has drawn…
Compass Therapeutics, Inc. recently appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective January 1, 2026, adding deep oncology commercialization and clinical development experie…
Compass Therapeutics BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple hum…
(RTTNews) - Compass Therapeutics, Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, on Monday announced that it has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, ef…
Compass Therapeutics BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple hum…
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 12 best multibagger stocks to buy heading into 2026.Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment On December 3, 2025, Compass Therapeutics, Inc. (NASDAQ:CMPX)…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Compass Therapeutics, Inc. (CMPX) is a stock that can certainly grab the attention of many investors, b…
Compass Therapeutics BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that…
Thinkstock Quick Read After a brutal Monday, investors were treated to a snap-back rally in stocks on Tuesday. All of the major indices and Cryptocurrencies finished the day higher on Tuesday as hopes for an interest rate cut remained posi…